1. A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab
- Author
-
Hirofumi Tazawa, Haruna Kubota, Takashi Onoe, Toshiaki Komo, Haruki Sada, Yosuke Shimizu, Hirotaka Tashiro, Shunya Tahara, Takahisa Suzuki, Takeshi Sudo, Naoto Hadano, Wataru Shimizu, and Kohei Ishiyama
- Subjects
0301 basic medicine ,Peritoneal metastasis ,medicine.medical_specialty ,Advanced gastric cancer ,medicine.medical_treatment ,Case Report ,lcsh:RC254-282 ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Ascites ,medicine ,Adverse effect ,Chemotherapy ,Performance status ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,Nivolumab ,Oncology ,Docetaxel ,030220 oncology & carcinogenesis ,medicine.symptom ,business ,medicine.drug - Abstract
Peritoneal metastasis (PM) is detected in 14% of gastric cancers at the time of initial diagnosis, with a median survival time of 4 months. A 66-year-old woman diagnosed with cT4a(SE) N2M1(LYN) cStage IV was treated with three lines of chemotherapy for a year. During the third line of chemotherapy, computed tomography (CT) scan revealed a large amount of ascites, periportal collar sign, and bilateral ureteral stenosis owing to PM. The tumor biomarkers (CEA and CA 19–9) remained elevated similar to the initial levels. The patient was administered 3 mg/kg nivolumab intravenously biweekly as the fourth line of chemotherapy. Three months after the nivolumab treatment, gastroscopy revealed an extreme reduction of the tumor size, while CT scan revealed the absence of ascites and a well-controlled tumor. There was no immune-related adverse event with nivolumab during and after the treatment, and performance status improved to 0. The patient has been alive for about 2.5 years since her first visit with her sixth line of chemotherapy (docetaxel). We report a case of advanced gastric cancer with PM that was treated successfully with nivolumab.
- Published
- 2019